In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Transcept grants Intermezzo rights to Purdue Pharma

Executive Summary

Transcept Pharmaceuticals (neurology), which reverse merged with Novacea last September to go public, has signed its first commercialization agreement: it is licensing pain-focused Purdue Pharma and an undisclosed affiliate exclusive US rights to Intermezzo, a low-dose version of zolpidem (in higher doses, the drug is sold under the brand Ambien) that has the potential to be the first-ever prescribed product for middle-of-the-night awakenings for insomnia patients. Purdue has the right to negotiate a license for Canada and Mexico.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies